EUVIMEDEUVIMED entdecken
Crossref

BEYOND SINGLE BIOMARKERS: THE CASE FOR COMPOSITE INDICES IN ASTHMA PHENOTYPING AND SEVERITY ASSESSMENT

Sulthan Salauddin, Mohammed Sameer Ahmed, Karthik Velimala, Anoop Gurram, A. Praveen Reddy, V. Srujana

International Journal of Medicine and Public Healt · 05.11.2026 · 16 (4) · 1516-1522

DOI: 10.70034/ijmedph.2026.4.231 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Medicine and Public Healt, online erschienen am 25.10.2026. Verfasst von Sulthan Salauddin und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Asthma is a heterogeneous disease characterized by diverse inflammatory pathways, clinical presentations, and treatment responses. Traditional approaches relying on single biomarkers have proven insufficient for capturing this complexity, often failing to adequately phenotype patients or predict disease severity and therapeutic outcomes. Materials and Methods: This narrative review synthesizes current evidence on composite biomarker approaches in asthma phenotyping and severity assessment. We examined studies evaluating multi-biomarker panels, composite scoring systems, and integrated assessment tools that combine inflammatory, immunological, and clinical parameters.

Results

Composite biomarker indices demonstrate superior performance over single markers in distinguishing asthma phenotypes, predicting exacerbation risk, and guiding biologic therapy selection. Multi-parameter approaches incorporating Type 2 inflammatory markers show enhanced discriminatory capacity and improved correlation with disease severity. Emerging composite tools integrate blood eosinophils, fractional exhaled nitric oxide, serum periostin, and IgE levels to create multidimensional profiles that better reflect the underlying inflammatory complexity of asthma.

Conclusion

Composite biomarker indices represent a paradigm shift toward precision asthma management, offering more balanced patient stratification than single-marker approaches. Their integration into clinical algorithms holds promise for optimizing therapeutic decisions, particularly in the era of targeted biologics.

Zitieren

APA

Salauddin, S., Ahmed, M. S., Velimala, K., Gurram, A., Reddy, A. P., & Srujana, V. (2026). BEYOND SINGLE BIOMARKERS: THE CASE FOR COMPOSITE INDICES IN ASTHMA PHENOTYPING AND SEVERITY ASSESSMENT. International Journal of Medicine and Public Healt, 16(4), 1516-1522. https://doi.org/10.70034/ijmedph.2026.4.231

Vancouver

Salauddin S, Ahmed MS, Velimala K, Gurram A, Reddy AP, Srujana V. BEYOND SINGLE BIOMARKERS: THE CASE FOR COMPOSITE INDICES IN ASTHMA PHENOTYPING AND SEVERITY ASSESSMENT. International Journal of Medicine and Public Healt. 2026;16(4):1516-1522. doi:10.70034/ijmedph.2026.4.231

BibTeX
@article{Salauddin2026,
  author = {Salauddin, Sulthan and Ahmed, Mohammed Sameer and Velimala, Karthik and Gurram, Anoop and Reddy, A. Praveen and Srujana, V.},
  title = {BEYOND SINGLE BIOMARKERS: THE CASE FOR COMPOSITE INDICES IN ASTHMA PHENOTYPING AND SEVERITY ASSESSMENT},
  journal = {International Journal of Medicine and Public Healt},
  year = {2026},
  volume = {16},
  number = {4},
  pages = {1516--1522},
  doi = {10.70034/ijmedph.2026.4.231}
}
Kostenlos starten →